You are here:

Forthcoming Submission: asparaginase (Spectrila)

Indication: Component of antineoplastic combination therapy for the treatment of acute lymphoblastic leukaemia in paediatric patients from birth to 18 years and adult patients.

Drug Details

Drug Name: asparaginase (Spectrila)
Drug Manufacturer: Medac Pharmaceuticals
BNF Category:
Submission type: Abbreviated Submission
SMC Meeting Date: 6/03/2018
Advice Due: 9/04/2018